Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of intraperitoneal M701 versus paracentesis drainage for malignant ascites from advanced epithelial solid tumors
CTR20240712Phase 3Completed
- Sponsor
- YZY Biopharma
- Start
- Mar 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of M701 in malignant ascites, ovarian cancer, gastric cancer (GC), colorectal cancer (CRC), sponsored by YZY Biopharma. Started Mar 2024; status: completed.
02
Drugs
M701
03
Conditions
malignant ascitesovarian cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20240712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240712.